3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

1 hour ago 5

Trey Thoelcke

Thu, June 25, 2026 astatine 7:15 AM CDT 5 min read

Quick Read

Crinetics Pharmaceuticals leads arsenic the cleanest buyout campaigner astatine $3.79 billion; Cytokinetics' FDA-approved Myqorzo attracts Bristol Myers Squibb oregon Novartis but costs $10.86 billion.
ARWR's ARO-INHBE astir doubled tirzepatide's value nonaccomplishment successful combination, but its $11 cardinal marketplace headdress makes an outright acquisition unlikely.
Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Cytokinetics didn't marque the cut. Grab the names FREE today.

Large-cap pharma is backmost successful the woody market. AbbVie's (NASDAQ: ABBV) pending acquisition of Apogee Therapeutics signaled that large buyers volition wage up for de-risked objective assets. Patent cliffs approach, GLP-1 franchises assemblage in, and cardio and endocrine portfolios astatine majors look thin. That backdrop puts a fistful of under-followed biotech names squarely successful the crosshairs.

A elephantine firm fig examines biotech flasks labeled Arrowhead, Cytokinetics, and Crinetics arsenic a patent scroll falls disconnected a cliff adjacent a Wall Street sign.

Credible takeover targets need:

An approved oregon launching commercialized merchandise with traction
Differentiated level oregon franchise assets
Manageable marketplace headdress
Clear strategical acceptable with a apt acquirer
A cleanable equilibrium expanse
Near-term catalysts to warrant a bid premium

No deals person been announced for the 3 names below. Here we fertile which biotech is the cleanest acceptable for the adjacent pharma buying spree.

3. Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals (NASDAQ: ARWR) sits astatine the strategical apical of this database yet ranks 3rd connected acquirability. The RNAi level institution has crossed into commercialized signifier with Redemplo (plozasiran), FDA-approved for familial chylomicronemia syndrome astatine a $45,000 WAC per year, with much than 400 full prescriptions and astir 30 caller play scripts, of which 85% are naive to the APOC3 class.

The obesity readouts are what ample pharma wants. ARO-INHBE delivered 9.4% value nonaccomplishment astatine week 16 combined with tirzepatide, astir treble tirzepatide alone, alongside 76.7% liver abdominous reduction. Arrowhead carries $1.78 cardinal successful currency pursuing a $930 cardinal superior raise, and precocious locked successful a Novartis ARO-SNCA Parkinson's woody worthy $200 cardinal upfront.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Cytokinetics didn't marque the cut. Grab the names FREE today.

The drawback is price. Shares are up 400.0% implicit the past twelvemonth to $79.81, with a marketplace headdress adjacent $11.2 billion. A level this wide is much apt to support signing partnerships than to merchantability outright.

2. Cytokinetics

Cytokinetics (NASDAQ: CYTK) has been a perennial cardiovascular takeout name. The lawsuit strengthened with the December 2025 FDA support of MYQORZO (aficamten) successful obstructive hypertrophic cardiomyopathy. The archetypal commercialized 4th delivered $4.79 cardinal successful nett merchandise gross crossed astir 680 patients, with much than 1,400 HCPs REMS certified and EU positive China NMPA approvals already successful hand.

Read Entire Article